Corporate
Otsuka Group Selected for CDP Climate Change A List
Nutraceuticals
Announcement of Price Revisions for Specified Products
Corporate
Otsuka Pharmaceutical Tokushima Itano Factory Receives2022 Minister of Economy, Trade and Industry Award for Excellent Greening
Nutraceuticals
New skin care brand Introducing Sakuraé Double Action Serum - Japan's first "double brightening" effect -
Nutraceuticals
Otsuka Pharmaceutical Finalizes Business Collaboration Agreement for Horizontal Recycling of PET Bottles
Nutraceuticals
Favorable Decision of the Supreme Court on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Pharmaceuticals
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225mg for Preventive Treatment of Migraine
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR® gene therapy candidate
Corporate
Otsuka Opens Osaka Research Center for Drug Discovery in Osaka Prefecture, Japan
Pharmaceuticals
Avanir Pharmaceuticals, Inc. Business Will Be IntegratedInto Otsuka America Pharmaceuticals, Inc. as of January 1, 2023
Nutraceuticals
Otsuka Pharmaceutical Supports Tokyo Legacy Half Marathon 2022Helping runners to complete the distance and set new records
Pharmaceuticals
Otsuka and Jolly Good to Launch FACEDUO, a Virtual Reality Support Program forPatients with Schizophrenia and Their Supporters
Nutraceuticals
Announcement of Price Revisions for Applicable Products
Pharmaceuticals
Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
Nutraceuticals
Launch of OTSUKA BLUE PLANET in IndonesiaSustainability Program Aims to Contribute to Local Environmental Efforts
Pharmaceuticals
Otsuka announces EC approval of Lupkynis® (voclosporin) as first oral treatment for active lupus nephritis
Nutraceuticals
Launch of SOYJOY Sweet PotatoPopular ingredient flavors new whole-soy nutrition bar
Pharmaceuticals
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application forAripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia andBipolar I Disorder in Adults
Pharmaceuticals
Otsuka Pharmaceutical announces positive results of phase III trial in Japan for brexpiprazole in the treatment of major depressive disorder
Pharmaceuticals
Otsuka Measurement Kit to be Covered by National Health Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
Nutraceuticals
Otsuka Subsidiaries Become Official Supporters of ASEAN Football Federation ChampionshipContributing to Safe Tournament Management and Optimum Conditioning for Players and Staf
Nutraceuticals
Announcement of Price Revisions for Applicable Products
Pharmaceuticals
European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia
Pharmaceuticals
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Nutraceuticals
Presentation of Research Regarding Compounds Contributing to Alleviation of Premenstrual Symptoms
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
Pharmaceuticals
Otsuka receives positive CHMP opinion for LupkynisTM (voclosporin)for the treatment of active lupus nephritis
Nutraceuticals
Introducing New B240 TabletsEffortless way to consume a unique ingredient for maintenance of physical condition
Corporate
Full-scale Launch of "Kenkokeiei Tsunagaru Support" ServiceOtsuka Pharmaceutical Supports Resolution of Health Issues for Small & Medium-sized Enterprises
Nutraceuticals
POCARI SWEAT 250ml Returnable Bottle For Distribution via Circular Shopping Platform 'Loop'
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
Pharmaceuticals
European Medicines Agency Commences Review of Aripiprazole2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
Pharmaceuticals
Otsuka Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Enters Collaboration with xFOREST Therapeutics on RNA Structure- Targeted Drug Discovery Covering Multiple Diseases
Nutraceuticals
Otsuka Pharmaceutical Publishes Paper Investigating Binding Property of Salivary IgA on Pathogenic Microorganisms
Pharmaceuticals
Launch in Japan of Moizerto® Ointment, a Treatment for Atopic Dermatitis
Nutraceuticals
POCARI SWEAT × TOKUSHIMA VORTIS Football Dream ProjectOtsuka and Tokushima Vortis collaborate to support overseas promotion of health through sports activities and regional vitalization in Tokushima
Pharmaceuticals
Launch in Japan of SAMTASU® for IV Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Announcement of Termination of Global License Agreements for Renal Anemia Treatment with Akebia Therapeutics, Inc.
Corporate
Four Otsuka Group Companies in Indonesia Adopts CO2-Free Electricity - Approximately 13% reduction in annual CO2 emissions -
Pharmaceuticals
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
Corporate
Otsuka Group Joins RE100 International Initiative - Committed to 100% Renewable Energy -
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
Pharmaceuticals
Akebia Therapeutics Receives Complete Response Letter from U.S. FDAfor Vadadustat for the Treatment of Anemia associated with Chronic Kidney Diseasein Adult Patients
Pharmaceuticals
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
Pharmaceuticals
Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Corporate
Packaging for a Sustainable FuturePOCARI SWEAT to Introduce Recycled PET for Bottles from Spring 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.8 KB)
Nutraceuticals
～Otsuka Pharmaceutical Survey of "Working Women's Health Consciousness"～ Indication that women’s health concerns (PMS, menopause) significantly affect career paths. Need for recognition as "corporate issues" beyond individual efforts.
Nutraceuticals
Introducing New Calorie Mate BLOCK VanillaNutritional Balance in Everyday Life for People of All Ages
Nutraceuticals
Otsuka Extends Its Deep Expertise in Soy-Based Products to Launch SOYJOY 100% Plant-Based Series
Corporate
Favorable Judgment on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Corporate
Otsuka Pharmaceutical Certified as Sports Yell Company for 5th Consecutive Year- Collaboration among Otsuka Group Companies to Support Employees' Ongoing Fitness Efforts -
Pharmaceuticals
Otsuka Enters Agreement with Jolly Good for Co-Development and Sales Rights in Japanfor a Social Skills Training Platform Using Virtual Reality in the Psychiatric Field
Corporate
Favorable judgment on lawsuit for revocation of trial decision on patent right held in relation to equol-containing foods
Pharmaceuticals
Otsuka and Lundbeck Announce U.S. FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) to Treat Schizophrenia in Pediatric Patients
Pharmaceuticals
Otsuka and Rebirthel Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology
Nutraceuticals
Launch of tocoelle Supplement - Gentle support for pre-menstrual fluctuations -
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
Corporate
Otsuka Group Supports Recommendations of the Task Force on Climate-related Financial Disclosure (TCFD) -Joins TCFD Consortium-
Pharmaceuticals
Otsuka Measurement Kit to Assist in Diagnosis and to Monitor Treatment Effectiveness for Acute Lymphoblastic Leukemia (ALL), to be Covered by Health Insurance in Japan
Pharmaceuticals
Otsuka submits initial marketing authorization application to the European Medicines Agency for vadadustat for the treatment of adults with anemia associated with chronic kidney disease
Pharmaceuticals
Otsuka Announces Approval in EU of Pediatric, 25 mg Dispersible-Tablet Formulation of Deltyba™ for Multidrug-Resistant Tuberculosis
Pharmaceuticals
Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaborationand License Agreement for Four Psychiatry and Neurology Compounds
Pharmaceuticals
Otsuka's Moizerto® Ointment Granted Approval in Japan as a Treatment for Atopic Dermatitis
Pharmaceuticals
Otsuka announces that Novartis Pharma's ENTRESTO® received a new indication for treatment of hypertension in Japan
Corporate
100th Anniversary of Otsuka Group of Companies Looking Ahead to the Next 100 Years
Pharmaceuticals
Otsuka to Launch AJOVY® Subcutaneous Injection 225 mg Syringe in Japan
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
Pharmaceuticals
Otsuka Obtains Approval in Japan for Orally-Disintegrating-Dose Form of REXULTI® Tablets
Pharmaceuticals
Otsuka reports topline outcomes on a phase II trial that evaluated brexpiprazole for the treatment of borderline personality disorder
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at National Junior High School Championships 2021Supporting safe extracurricular sports activities and event operation
Pharmaceuticals
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
Nutraceuticals
Production and Sales of Fibe-Mini Begin in Indonesia
Nutraceuticals
Reflecting Customer Concerns Introduction of ORONAMIN C DRINK in Label-free Bottles
Nutraceuticals
U.S. Supplement Brand Nature Made Marks 50th Anniversary/Named #1 Pharmacist Recommended Vitamin and Supplement for 24 Years
Nutraceuticals
Otsuka Pharmaceutical Responds to New Lifestyles with Measures for Prevention of Heat Disorders at Inter-High 2021 Supporting safe operation and health of competitors and officials for summer Inter-High School Championships
Nutraceuticals
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Uqora, a provider of women's urinary tract health products
Pharmaceuticals
Otsuka Files Application in Japan for Approval of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Pharmaceutical and Shanghai Rightongene AnnounceCollaboration to Commercialize WT1 mRNA Assay Kit in China
Pharmaceuticals
Otsuka Obtains New, High-Sensitivity Biomarker Measurement Technology- Technology using surface plasmon field-enhanced fluorescence spectroscopy -
Pharmaceuticals
Otsuka Has Filed a Marketing Authorization Application to the European Medicines Agency for Voclosporin for the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
AJOVY® Subcutaneous Injection 225 mg Syringe, as a Preventive Treatment of Migraine, Granted Approval in Japan
Pharmaceuticals
Approval in Japan for Otsuka's minor BCR-ABL mRNA measurement kit A marker to monitor treatment effectiveness for acute lymphoblastic leukemia (ALL)
Pharmaceuticals
Quick NaviTM - Flu+COVID-19 Ag Receives Regulatory Approval in Japan as a Combo, Rapid Diagnostic Kit for Influenza and COVID-19- Simultaneous testing for both viruses using a single test sample -
Corporate
Otsuka Group Complete Introduction of CO2-free Electricity for All 23 Manufacturing Facilities in Japan -Contributing to a more than 40% reduction in annual CO2 emissions in Japan-
Pharmaceuticals
Otsuka and Akebia Announce U.S. FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
Corporate
Otsuka Group Company, A&P Inphatec, Commences Sales in U.S. of XylPhi-PD™,a Bactericidal Treatment for Pierce's Disease in Grapevines
Corporate
Otsuka Pharmaceutical Receives First Certification as Tokyo Metropolitan Government Sports Promotion Model Company (Practical Division) Recognized for providing opportunities for exercise adapted for new lifestyles
Pharmaceuticals
Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
Pharmaceuticals
Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia's Vadadustat
Pharmaceuticals
Otsuka to Launch QuickNaviTM-H.pylori, a Helicobacter pylori Quick Detection Kit- Test results in eight minutes and stool collection tools provided in one pack -
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Regulatory Approval of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
New Drug Application for Oral Disintegrated Tablet Formulation of TAKECAB® for Treatment of Acid-Related Disease
Pharmaceuticals
Otsuka and Perception Neuroscience Announce Collaboration on Development of PCN-101 (R-ketamine) in Japan for Treatment of Depressive Disorders
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuticals
A Delicious Snack That's Good for You Announcing SOYJOY Coffee & Nuts Soy protein from low-GI whole soy
Nutraceuticals
Convenient Sizes of UL·OS Medicated Scalp Shampoo and Medicated Skin Wash Launched to Promote Trial Use
Corporate
Otsuka to Construct a Drug Discovery Center in Osaka Prefecture, Japan
Corporate
Office Divisions of Five Otsuka Group Companies to Switch to Green Power
Pharmaceuticals
Otsuka and Illumina Announce Agreement on Development and Commercialization of IVD Test Kit for Patients in Japan with Blood Cancer
Corporate
Otsuka Pharmaceutical Certified as Sports Yell Company for 4th Consecutive Year -Providing Opportunities for Exercise Tailored for New Lifestyles-
Corporate
Otsuka Pharmaceutical to Transfer All Shares of Bean Stalk Snow to Megmilk Snow Brand
Nutraceuticals
Introduction of POCARI SWEAT Label-free Bottles Revamped packaging to contribute to a sustainable society
Pharmaceuticals
Formation of a Licensing Agreement Covering Japan and Europe for the Lupus Nephritis Drug "Voclosporin"
Nutraceuticals
Otsuka Pharmaceutical Signs On as "B. League Supporting Company" -To cooperate with physical conditioning and regional healthcare-related initiatives-
Nutraceuticals
UL·OS Medicated Scalp Shampoo and Medicated Skin Wash to Appear in New Packaging
Pharmaceuticals
Quick NaviTM Rapid Diagnostic Test in Japan Now Supports Simultaneous Testing for Influenza and COVID-19 Through Collection of a Single Testing Sample
Nutraceuticals
Debut of InnerSignal Skin Care Brand Outside Japan - Launched in South Korea as Functional Cosmetics with Two Key Benefits -
Pharmaceuticals
Otsuka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
Pharmaceuticals
Positive Top-Line Results in Phase 3 Trial of OPC-61815, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Quick NaviTM-COVID 19 Ag Rapid Diagnostic Test in Japan Now Enables Test Sample Collection from Front of Nasal Cavity
Corporate
Otsuka Group Acquires ISO 14001 Certification -Reinforcement of group-wide environmental initiatives-
Pharmaceuticals
Otsuka Has Filed an Application in Japan for Approval of Difamilast (OPA-15406) as an Atopic Dermatitis Drug
Pharmaceuticals
Otsuka's ABILIFY MAINTENA approved for the additional indication of bipolar I disorder in Japan
Nutraceuticals
- Creating a Society that Supports Ongoing Employee Health - Full-scale launch of "Kenko Shacho" community website connecting corporate leaders
Nutraceuticals
Smart Nutrition for New Lifestyles Announcing SOYJOY Green Tea & Macadamia Moist Texture Highlights the Mellow Astringency and Savor of Green Tea
Nutraceuticals
Otsuka Pharmaceutical Supports High School Students in Summer 2020 Supporting events across Japan that are close to their hearts, including alternative athletic competitions
Pharmaceuticals
Top-line Results from Global Phase 3 Program of Vadadustat, a Drug Candidate for Treatment of Renal Anemia due to Chronic Kidney Disease in Non-Dialysis Patients
Pharmaceuticals
Novartis Pharma and Otsuka to Launch Entresto® Tablets in Japan for Patients with Chronic Heart Failure
Pharmaceuticals
Otsuka to Co-market New Diagnostic Test for COVID-19, Quick Navi-COVID 19 Ag-Confirmation of test results in just 15 minutes, and easy-to-read results shown in two contrasting colors-
Pharmaceuticals
Otsuka Filed Application in Japan for Approval of Fremanezumab as a Prophylactic Treatment for Migraine
Pharmaceuticals
Otsuka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML
Pharmaceuticals
Novartis Pharma obtains manufacturing and marketing approval in Japan for Entresto® tablet as angiotensin receptor neprilysin inhibitor (ARNI) for chronic heart failure
Pharmaceuticals
Samsca®approved in Japan for additional indication of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Pharmaceuticals
Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in CNS indications
Pharmaceuticals
Clinical program for NY-ESO-1/siTCRTM gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
Pharmaceuticals
Japan's MHLW grants Sakigake Designation to comprehensive genomic profiling assay for hematologic malignancies co-developed by Otsuka
Nutraceuticals
Introduction of Set of Heat Disorder-related Teaching Materials: "Get Back That Sweat! Preventing Heat Disorders Together"
Pharmaceuticals
Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension
Pharmaceuticals
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
Pharmaceuticals
Deltyba® (delamanid) approved in Russian Federation for treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB)
Pharmaceuticals
Launch of Aspirin/Vonoprazan Fumarate Combination Tablets: "Cabpirin® Combination Tablets"
Pharmaceuticals
Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Corporate
Otsuka Pharmaceutical to use CO2-free electricity at all plants in Japan (PDF: 96.4 KB)
Nutraceuticals
Research on the Relationship Between Hair Problems and Capacity to Produce Equol
Pharmaceuticals
Otsuka Enters into Licensing Agreement in Japan for Bempedoic Acid, a Treatment for Hypercholesterolemia
Pharmaceuticals
Otsuka to Introduce QuickNaviTM-Adeno2, an Adenovirus Quick Measurement Kit- Faster and clearer test results with two contrasting colors -
Pharmaceuticals
Development of the first comprehensive genomic profiling assay for hematologic malignancies in Japan- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a project to evaluate its clinical utility -
Pharmaceuticals
Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)
Pharmaceuticals
Otsuka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
Pharmaceuticals
Cabpirin® Combination Tablet Receives Regulatory Approval in Japan for Treatment of Acid-related Diseases in Patients Needing Low-dose Aspirin
Nutraceuticals
Dietary Education App "SketchCook" Recognized with Ministry of Education, Culture, Sports, Science and Technology（MEXT） "Award for Companies Promoting Experience-based Learning Activities for Youth 2019"
Nutraceuticals
Newly published findings on inhibitory effect of near-infrared (IRA) radiation on human epidermal cell proliferation and potential mechanisms
Corporate
Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors (PDF: 57.4 KB)
Nutraceuticals
Introducing InnerSignal Rejuvenate ONE－All-in-One Skin Care Product with Time-Lapse Penetration Combines Lightening and Three Basic Skin Care Functions－
Pharmaceuticals
Otsuka enters into co-promotion agreement for angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 in Japan
Pharmaceuticals
First-of-its-kind global collaboration launched to develop transformative treatment regimens for tuberculosis
Pharmaceuticals
Otsuka Pharmaceutical Establishes Subsidiary in Malaysia
Nutraceuticals
Introducing New UL·OS Face & Body Sheet A single sheet provides convenient facial and body care
Nutraceuticals
Launch of "Health Support Plus" Service to manage workforce health based on desknet's NEO groupware
Nutraceuticals
Whole soy nutrition bar delivers the same satisfying crunchy texture with a significant reduction in sugars SOYJOY Peanuts Renewal Launch
Pharmaceuticals
Otsuka Pharmaceutical and the Japan Kidney Association Form Collaborative Agreement -Aim to identify practical uses of basic research in the kidney field-
Pharmaceuticals
Otsuka announces that subsidiary Astex Pharmaceuticals' NDA for ASTX727 (oral C-DEC), for the treatment of MDS and CMML, has been accepted for priority review by the U.S. FDA
Nutraceuticals
Tokyo Marathon 2020 - Connecting With the World Otsuka Pharmaceutical to be an Official Partner for 14th consecutive year
Nutraceuticals
Otsuka Pharmaceutical Establishes Health Beverage Subsidiary in Mexico
Pharmaceuticals
Otsuka announces positive top-line results from clinical trials in Japan offremanezumab as a prophylactic treatment for migraine
Corporate
Otsuka Pharmaceutical Awarded Grand Prize in Tokyo Metropolitan Government Women's Participation Awards for First Year of the Reiwa Era
Pharmaceuticals
Otsuka enters multi-project drug discovery collaboration with PhoreMost Limited
Corporate
Announcement of Changes in Company Officers at Otsuka Pharmaceutical Co., Ltd. (PDF: 65.0 KB)
Pharmaceuticals
Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA® Combination Ophthalmic Solution
Pharmaceuticals
POConePlus® Infrared Spectrophotometer for Diagnosis of H. pylori infection launched in Japan
Corporate
Construction Completed on Otsuka's New Pharmaceutical Factory Plant in Mima City, Tokushima Prefecture, Japan
Pharmaceuticals
Otsuka Launches New SAMSCA Formulation in Japan: SAMSCA® OD Tablets
Corporate
Otsuka Pharmaceutical Cosponsors "Asan Walking Festa in Itano" as Part of Community Health Promotion Efforts
Pharmaceuticals
Otsuka Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development ofInvestigational AVP-786 for the Treatment of Agitation in Patients with Alzheimer's Dementia
Pharmaceuticals
RS Virus Rapid-measurement Kit Quick NaviTM-RSV2 To Be Launched in Japan- Faster test results and enhanced visual features with two color lines -
Nutraceuticals
Presentation of Effects of lactic acid bacterium B240 at Palynological Society of Japan
Nutraceuticals
Three New Flavors of Easy-to-Drink Balanced Nutrition BeverageIntroducing Calorie Mate Liquid
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Reports Top-line Data from Second Phase 3 Trial Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
Pharmaceuticals
Otsuka Applies for the Additional Indication in Japan of Bipolar Disorder for ABILIFY MAINTENA for Suspended Release Injectable Suspension
Nutraceuticals
New Series Expands the SOYJOY Line of Whole Soy Nutrition Bars SOYJOY Scone Bar Plain
Corporate
Otsuka Pharmaceutical Greenhouse Gas Emissions Reduction Targets Earn Science Based Targets (SBT) Initiative Certification
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreement with Niigata Prefecture to Support Prefectural Residents' Health Promotion Project
Pharmaceuticals
Approval for the Additional Formulation of Samsca® OD Tablets in Japan
Nutraceuticals
UL·OS Men's Skincare BrandRenewal Launch of Three Moisturizing Products
Corporate
Otsuka Group Adopts CO2-free Electricity Annual CO2 Emissions to Decline by Approximately 9%
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink PRESENTS Awa Odori Sound Festival
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Nagano Prefecture
Nutraceuticals
POCARI SWEAT Marketing Wins Top Prize at Japan Marketing Awards
Nutraceuticals
Deliciously Illustrated SketchCook Wins in Three Categories at PR Awards Asia 2019 ― Dietary education app promotes awareness about the importance of meals and nutrition to children―
Pharmaceuticals
Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
Pharmaceuticals
Otsuka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727
Pharmaceuticals
Otsuka and Japan Kidney Associationto Collaborative on Autosomal Dominant Polycystic Kidney Disease
Pharmaceuticals
Erdafitinib Receives Regulatory Approval in U.S.
Nutraceuticals
EQUELLE: Dietary Supplement to Support Women's HealthExpansion of US business through launch of sales via D-to-C channel
Nutraceuticals
Otsuka Pharmaceutical Establishes Health Beverage Subsidiary in Myanmar
Nutraceuticals
Otsuka Pharmaceutical to Sponsor 30th Southeast Asian Games 2019 (Philippines)
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Reports Phase 3 Data Evaluating Investigational AVP-786 for the Treatment of Moderate-to-Severe Agitation in Patients with Alzheimer's Dementia
Pharmaceuticals
Notice regarding the conclusion of co-development/co-promotion activities in Japan for the anti-epileptic drug "E Keppra"
Corporate
Otsuka Pharmaceutical Reappointments and New Appointments of Board Members and Statutory Auditors (PDF: 56.8 KB)
Pharmaceuticals
Selincro Tablets 10mg Launched in Japan
Nutraceuticals
Refreshing Men's Facial Lotion for Summer ComfortIntroducing UL·OS Medicated Skin Breezy LotionA single product to moisturize, minimize oily shine, and prevent formation of blemishes
Nutraceuticals
Otsuka Pharmaceutical to Serve as an Official Partner for Tokyo Marathon 2019New "Run," "Support," "Boost," Program Benefits All Participants
Pharmaceuticals
Otsuka and Lundbeck report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
Pharmaceuticals
Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"
Pharmaceuticals
Avanir Pharmaceuticals, Inc. Reaches Agreement in Principle with U.S. Department of Justice Regarding NUEDEXTA (dextromethorphan HBr and quinidine sulfate) 20 mg/10 mg capsule
Pharmaceuticals
The 1st Japan Open Innovation Prize
Nutraceuticals
Introducing SOYJOY Crispy Sakura Special Seasonal Flavor from SOYJOY Brand of Whole Soy Nutrition Bars
Pharmaceuticals
Selincro (nalmefene) Tablets 10mg Receives Regulatory Approval in Japan
Pharmaceuticals
Otsuka and Click Therapeutics Collaborate to Develop and Commercialize Digital Therapeutics for Patients with Major Depressive Disorder
Pharmaceuticals
Otsuka subsidiary Avanir and Optinose agree to terminate license agreement for migraine treatment ONZETRA®Xsail®
Pharmaceuticals
Otsuka and Lundbeck report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)
Pharmaceuticals
Quick Navi-Reader for Diagnosis of Influenza to be Launched in Japan
Pharmaceuticals
Otsuka and Proteus Digital Health Announce Expanded Collaboration Agreement to Advanced Digital Medicines for Mental Health
Nutraceuticals
Launch of Nationwide Retail Distribution of "Barrier Beverage" BODYMAINTÉ Drink
Pharmaceuticals
Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults
Corporate
Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors "Asan Walking Festa in Itano"
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Executive LicensingAgreement on Novel "CAR-T Cell Therapy" for Multiple Myeloma
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink PRESENTS Awa Odori Sound Festival
Pharmaceuticals
Otsuka and Lundbeck's Rxulti® (brexpiprazole) approved by the European Commission
Pharmaceuticals
Otsuka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
Nutraceuticals
Focus on Core Temperature as a Heat Disorder Countermeasure - New POCARI SWEAT ICE SLURRY "Cools from the Core" -
Pharmaceuticals
Otsuka Pharmaceutical to Acquire Visterra
Nutraceuticals
Launch of SOYJOY Manufacturing and Marketing in Indonesia
Nutraceuticals
Expansion of Overseas Marketing of POCARI SWEAT ION WATER July 2018 Marks Official Launch in Singapore
Pharmaceuticals
Otsuka and Lundbeck's Rxulti® (brexpiprazole) receives positive opinion in EUfrom CHMP for the treatment of schizophrenia in adults
Nutraceuticals
ORONAMIN C DRINK Makes a Debut in Indonesia
Nutraceuticals
Luscious peach flavor evokes a summery mood - New SOYJOY Crispy Peach -
Pharmaceuticals
Otsuka and Lundbeck to Start Third Phase 3 Trial in June to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Alzheimer's Disease
Pharmaceuticals
Otsuka Pharmaceutical Establishes Subsidiary in Singapore
Nutraceuticals
May 18 Launch of "Deliciously Illustrated SketchCook"Children's cooking illustrations transformed into vivid images and recipes in an entertaining dietary education app using state-of-the-art AI technology to teach nutrition
Pharmaceuticals
Otsuka's JYNARQUE™ (tolvaptan) Approved by U.S. FDA as the First Treatment to Slow Kidney Function Decline in Adults at Risk of Rapidly Progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
REXULTI® Tablets, a New Antipsychotic Drug, Launched in Japan
Nutraceuticals
"Awake Refreshed, Revitalized" Kenja-no-Kaimin Sleep Rhythm Support, with a Foods with Function Claim, Now Available throughout Japan
Pharmaceuticals
Otsuka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Tottori Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Regional Revitalization Partnership with Kyoto Prefecture
Pharmaceuticals
Otsuka's DELTYBA Approved in China for the Treatment of Multidrug-resistant Tuberculosis
Nutraceuticals
Introducing EQUELLE Gelée, a Flavorful and Convenient Supplement from the EQUELLE Brand - Supports women's beauty and health from the inside out -
Corporate
Otsuka Pharmaceutical Appoints Board Members and Statutory Auditors (PDF: 55.9 KB)
Nutraceuticals
New addition to SOYJOY line of soy snack bars- SOYJOY Crispy Banana -
Nutraceuticals
New EQUELLE Gelée Supports the Fundamentals of Women's Beauty and Health- New from the trusted EQUELLE brand, a flavorful, convenient equol supplement -
Corporate
Otsuka Pharmaceutical Certified for Two Years in a Row as Excellent Health and Productivity Management Enterprise
Nutraceuticals
Otsuka Pharmaceutical Serves as Official Partner for Tokyo Marathon 2018 - Helping Runners Give Their Best Performance for 12th Consecutive Year -
Pharmaceuticals
Otsuka Awarded Grant to Advance Development of Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid
Nutraceuticals
Otsuka Introduces Conditioning Drink Version of BODYMAINTÉ
Corporate
Otsuka Signs Statement of Support for Women's Empowerment Principles (PDF: 218.9 KB)
Pharmaceuticals
Otsuka Receives Approval in Japan for the Manufacture and Sale of New Antipsychotic Drug Rexulti® Tablets for Schizophrenia
Nutraceuticals
Acquisition of BC BIO, French Organic Food Product Manufacturer - European subsidiary seeks to reinforce offering of organic food products -
Pharmaceuticals
Otsuka and DKSH to commence sales of Otsuka prescription drugs in Myanmar
Pharmaceuticals
Otsuka to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
Pharmaceuticals
Otsuka and X-Chem Enter into a Drug Discovery Research and License Collaboration (PDF: 119.0 KB)
Nutraceuticals
Otsuka Pharmaceutical Establishes Joint Research Chair for Women's Health Promotion with Hirosaki University Graduate School of Medicine
Pharmaceuticals
Otsuka Pharmaceutical Co., Ltd. Receives the Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis Japanese Government Grants Award for the First Time
Corporate
Otsuka Pharmaceutical Unveils It's Completely New Website
Corporate
Otsuka Pharmaceutical Receives Newly Established "Sports Yell Company" Certification from Japan Sports Agency
Nutraceuticals
Observational study of 88 female Kindai University athletes Relationship between premenstrual syndrome-induced interference in athletic performance and equol production status
Pharmaceuticals
Otsuka Pharmaceutical to Launch New, Pre-mixed Flavor Formulations (Fruit and Coffee) for Aminoleban EN, an Oral Nutritional Supplement for Patients with Liver Failure
Pharmaceuticals
Otsuka Pharmaceutical Launches New Formulations in Japan of L-Cartin® for Carnitine Deficiencies
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Regional Revitalization Partnership Agreement with Yamaguchi Prefecture
Corporate
Otsuka Pharmaceutical Cooperates with Community Health Promotion EffortsTokushima Itano Factory Sponsors "Asan Walking Festa in Itano"
Nutraceuticals
Otsuka Pharmaceutical to Become a Sponsor of the 18th Asian Games
Pharmaceuticals
Otsuka and Proteus Announce the First U.S. FDA Approval of a Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
Pharmaceuticals
U.S. FDA Accepts Otsuka's Resubmission to Support a Regulatory Review of Tolvaptan in the Treatment of ADPKD
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Partnership with Oita Prefecture
Pharmaceuticals
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Corporate
Otsuka Pharmaceutical Tokushima Wajiki Factory Receives2017 Minister of Economy, Trade and Industry Award for Excellent Greening, a First for the Shikoku Region
Pharmaceuticals
Otsuka and Lundbeck will Initiate a Third Phase 3 Trial to Evaluate Brexpiprazole in the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type
Nutraceuticals
US Launch of EQUELLE, a Dietary Supplement to Support Women's Health
Nutraceuticals
Heat Disorders Prevention - Communication Project "Hitosuzumi Awards 2017"Otsuka Pharmaceutical Recognized with "Team Excellence" and "Top Runner" Awards
Pharmaceuticals
Otsuka Submits a Japan NDA for Nalmefene, a Drug to Reduce Alcohol Consumption in Alcohol-Dependent Patients
Pharmaceuticals
Otsuka and Lundbeck Announce Initiation of Two Phase 3 Trials of Brexpiprazole in Patients with Bipolar I Disorder
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Kochi Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Ehime Prefecture
Pharmaceuticals
Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (DeltybaTM) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PDF: 467.1 KB)
Nutraceuticals
Extremely Fine-textured Foam Facial Cleanser Introducing UL·OS Face Wash for Skin Care Evolution of Face Wash from "Cleansing" to "Skin Care"
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink Presents Awa Odori Sound Festival
Pharmaceuticals
ABILIFY MAINTENA® (aripiprazole) for Extended-Release Injectable Suspension Approved by U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Pharmaceuticals
Otsuka Submits New Drug Application in Japan for Aripiprazole Sertraline Combination Tablets
Nutraceuticals
Otsuka Pharmaceutical to Acquire Daiya, a Rapidly Growing Plant-Based Food Company in North America
Nutraceuticals
Otsuka Pharmaceutical Serves as Special Sponsor of Summer Inter-High School Athletic Meeting for Fourth Consecutive Year Event Venue Enlivened with Heat Stroke Prevention Posters and Banners Submitted by Local High School Students
Pharmaceuticals
"Quick Navi-Flu2" Influenza Diagnostic Kit to Launch in Japan
Nutraceuticals
Otsuka Pharmaceutical Enters into Partnership Agreement with Wakayama Prefecture
Nutraceuticals
Otsuka Pharmaceutical Establishes New Functional Food and Beverage Affiliate in Thailand
Pharmaceuticals
Otsuka and R-Pharm Announce Licensing Agreement to Commercialize DeltybaTM (Delamanid) for Multidrug-Resistant Tuberculosis (MDR-TB) in Russia and CIS Countries (PDF: 99.9 KB)
Pharmaceuticals
Smart Medicine Container for Anti-stroke Medicine Approved for Sale in Japan
Pharmaceuticals
Quick NaviTM-Mycoplasma Diagnostic Kit to Launch in Japan
Pharmaceuticals
Nalmefene, a Drug Candidate to Reduce Alcohol Consumption, Shows Positive Results from Phase III Trial in Japan
Pharmaceuticals
Otsuka to Continue Commitment to Support the Global Health Innovative Technology Fund (GHIT Fund)
Pharmaceuticals
Additional Formulation of Samsca® Granules 1% Available in Japan
Nutraceuticals
Kenja-no-Kaimin Sleep Rhythm Support Asparagus-derived ingredient improves sleep-wake rhythms and enhances quality of sleep
Pharmaceuticals
Otsuka and Proteus Digital Heath Resubmit Application to US FDA for First Digital Medicine
Pharmaceuticals
Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S.
Corporate
Otsuka Pharmaceutical Announces Construction of New Pharmaceutical Manufacturing Facility, Tokushima Mima Factory
Corporate
Otsuka Agree to Purchase New Share Allocation of TWO CELLS
Pharmaceuticals
Otsuka and Teva Sign Licensing Agreement for Japan on Prophylactic Migraine Drug Candidate Fremanezumab (TEV-48125)
Corporate
Nutrition & Santé Inaugurates New Gluten-Free Manufacturing Facility
Pharmaceuticals
Otsuka and Lundbeck Announce Results of Brexpiprazole on Symptoms of Agitation Related to Alzheimer's-type Dementia
Pharmaceuticals
Otsuka and Akebia Concludes Licensing Agreement for Akebia's Renal Anemia Drug Vadadustat - Development and marketing territories include Europe, China, etc. -
Nutraceuticals
Renewal of Fibe-Mini Dietary Fiber Beverage Food for Specified Health Uses Now Contains Lycopene - Renewal Launch with New Package and Logo Design -
Nutraceuticals
Amino-Value 4000 and Amino-Value Powder 8000 Renewed as Foods with Function Claim "Alleviates Fatigue Caused by Physical Activity"
Nutraceuticals
Otsuka Pharmaceutical Introduces New BODYMAINTÉ Brand BODYMAINTÉ Jelly, a conditioning food to be launched in April 2017
Nutraceuticals
Otsuka Pharmaceutical Enters into Health-related Partnership with Fukui Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership Agreement with Ibaraki Prefecture
Pharmaceuticals
Lundbeck and Otsuka's Brexpiprazole for Adult Patients with Schizophrenia Accepted for Review by EMA
Pharmaceuticals
Ribociclib (LEE011) Receives Regulatory Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor
Pharmaceuticals
Approval for the Additional Formulation of Samsca® Granules 1% in Japan
Corporate
Otsuka Pharmaceutical Appoints Board Members and Statutory Auditors (PDF: 56.1 KB)
Pharmaceuticals
Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities
Pharmaceuticals
Otsuka Pharmaceutical to Acquire Neurovance, Inc. Acquisition of clinical-stage company in ADHD widens Otsuka's presence in mental health
Nutraceuticals
New Addition to Gerblé Line of Nutritional Food Products from Southern France - Prune & Fig Biscuits -
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Tochigi Prefecture
Corporate
Otsuka Pharmaceutical Certified as Excellent Health and Productivity Management Enterprise
Nutraceuticals
Otsuka Pharmaceutical Introduces New BODYMAINTÉ Brand BODYMAINTÉ Jelly, a conditioning food to support athletic performance to be launched in April 2017
Nutraceuticals
Otsuka Launches OATHAS Training Program for Healthy Aging Supporters Program to support pharmacies as health information bases with strong connections to local community
Pharmaceuticals
Health Canada Approves Otsuka and Lundbeck's REXULTI (brexpiprazole) as a Treatment for Schizophrenia in Adults
Nutraceuticals
Otsuka Pharmaceutical Supports Tokyo Marathon 2017 as Official Partner Providing comprehensive support for runners' conditioning for the 11th consecutive year
Pharmaceuticals
Osaka University and Otsuka Agree Comprehensive Collaboration : Joint Research Project with Immunology Frontier Research Center (IFReC) (PDF: 226.3 KB)
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Okinawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Health-related Agreement with Aichi Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion and Disaster Relief Supply Agreements with Kagawa Prefecture
Nutraceuticals
Introducing New SOYJOY Crispy White Macadamia Crunchy soy nutrition bar flavored with soy-based white chocolate and macadamia nuts
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Chiba Prefecture
Nutraceuticals
Blocks both Ultraviolet and Near Infrared Radiation Announcing New InnerSignal UV+IR Protect Makeup Base
Pharmaceuticals
Otsuka Files a Supplemental Application in Japan: A Plastic Case with Anti-Stroke Medicine for a Smart Medicine Container
Nutraceuticals
Hokkaido University and Otsuka Pharmaceutical to Collaborate in Joint Research (PDF: 213.0 KB)
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Shimane Prefecture
Pharmaceuticals
Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan
Pharmaceuticals
Otsuka Submits New Drug Application in Japan for Brexpiprazole in the Treatment of Schizophrenia
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Gunma Prefecture
Pharmaceuticals
Akebia Therapeutics and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.
Nutraceuticals
JSC High Performance Center Total Conditioning Research Project Joint research aims to promote sports medicine and science and boost international competitiveness (PDF: 190.3 KB)
Pharmaceuticals
Otsuka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Partnership with Nara Prefecture
Pharmaceuticals
FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of Abilify Maintena® (aripiprazole) For The Treatment Of Bipolar I Disorder
Corporate
Otsuka Joins UN Global Compact (PDF: 170.8 KB)
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreements with Hokkaido Government Entities - Partnership Agreement for Promotion of Hokkaido Residents' Health Initiatives - - Cooperative Accord for Children's Education and Sports Promotion -
Corporate
Otsuka Pharmaceutical Cooperates with Community Health Promotion Efforts Tokushima Itano Factory Sponsors Asan Walking Festival in Itano
Pharmaceuticals
ICLUSIG® Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
New 1 mg Tablet Dosage of Antipsychotic ABILIFY Available in Japan
Nutraceuticals
Relationship between PMS/PMDD and production status of soy isoflavone metabolite equol Presentation to the Japan Society for Menopause and Women's Health
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Hyogo Prefecture
Nutraceuticals
Heatstroke Prevention Communication Project Hitosuzumi Awards 2016 Otsuka Pharmaceutical Named "Best Communicator" for Third Consecutive Year Proactive Efforts to Raise Awareness Also Recognized with "Top Runner Award"
Nutraceuticals
ORONAMIN C DRINK Recognized with Good Design Long Life Design Award
Nutraceuticals
POCARI SWEAT Recognized with Good Design Long Life Design Award
Pharmaceuticals
Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with Otsuka's Subsidiary Astex Pharmaceuticals
Nutraceuticals
Otsuka Pharmaceutical Enters into Disaster Support Agreement with Fukui Prefecture
Pharmaceuticals
Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension
Pharmaceuticals
Antipsychotic ABILIFY Gains Approval in Japan for the Additional Indication of Irritability Associated with Pediatric Autism Spectrum Disorder
Pharmaceuticals
ICLUSIG® Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Pharmaceuticals
U.S. FDA Approves Labeling Update of REXULTI®(brexpiprazole) for Maintenance Treatment of Schizophrenia in Patients in the U.S.
Pharmaceuticals
Headline conclusions from the phase III study of idalopirdine (Lu AE58054) for cognitive symptoms associated with Alzheimer's disease
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Yamanashi Prefecture
Pharmaceuticals
Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)
Pharmaceuticals
Otsuka and NEC agree to develop a smart medicine container to assist patients in taking daily anti-stroke medication at the appropriate time
Nutraceuticals
Otsuka Pharmaceutical Enters into Partnership Agreement with Yamagata Prefecture, Aiming to Achieve Japan's Top Healthy Life Expectancy
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Cooperative Agreement with Kanagawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Health Promotion Partnership with Kumamoto Prefecture
Pharmaceuticals
RIKEN CDB-Otsuka Pharmaceutical Collaboration Center launches (PDF: 90.0 KB)
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Toyama Prefecture
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima Exciting Summer in WAJIKI, Tokushima Awa Odori, Oronamin C Drink Presents Awa Odori Sound Festival
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Miyagi Prefecture
Corporate
Notice of Completion of Transfer of Shares Held by Otsuka Pharmaceutical Co., Ltd.
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Shizuoka Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Gifu Prefecture
Pharmaceuticals
ORALTAG™(iohexol), a New Oral Contrast Agent for Abdominal CT Scans, Launched in U.S. Developed by Otsuka Subsidiary Interpharma Praha
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Miyazaki Prefecture
Corporate
Otsuka Pharmaceutical Donates Funds for a Sub Rural Health Center in Myanmar For the stable provision of maternal and child health services
Pharmaceuticals
Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.
Corporate
Otsuka Pharmaceutical and IBM Japan to Set Up Joint Venture for Digital Health Solutions in Central Nervous System Field
Pharmaceuticals
VONOSAP® pack 400, VONOSAP® pack 800 and VONOPION®pack (triple-drug blister packs containing TAKECAB® tablet) Now Available for Helicobacter pylori* Eradication in Japan
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership Agreement with Akita Prefecture
Nutraceuticals
Thirst-quenching support for optimum day-to-day condition Introducing New POCARI SWEAT Ion Water Powder (to make 750ml)
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Fukushima Prefecture
Pharmaceuticals
"Neupro® Patch", a Dopaminergic, Anti-Parkinsonian Drug,Will Become Available in Japan in an Additional New Dosage, "Neupro Patch 18 mg"
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Nagasaki Prefecture
Corporate
Otsuka Pharmaceutical to Support Japan's COOL CHOICE Movement Cooperation in Public Awareness Campaigns to Encourage Wise Decisions to Counteract Global Warming
Corporate
Notice of Transfer of Shares Held by Otsuka Pharmaceutical Co., Ltd.
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Partnership Agreement with Osaka Prefecture
Nutraceuticals
Introducing Three New Flavors of Calorie Mate Jelly Focusing on the Need for a Nutritionally Balanced Jelly Beverage Option
Pharmaceuticals
FDA Issues Complete Response Letter For Digital Medicine New Drug Application
Nutraceuticals
Otsuka Pharmaceutical Enters into Health Promotion Partnership with Kagoshima Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Comprehensive Partnership with Mie Prefecture
Pharmaceuticals
Otsuka receives two commendations by the Japanese Government for the development of an anti-tuberculosis agent and an aquaretic/ADPKD treatment
Pharmaceuticals
Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
Nutraceuticals
Otsuka Pharmaceutical Launches "POCARI SWEAT & TOKYO Project" in Cooperation with Tokyo Metropolitan Government
Nutraceuticals
New POCARI SWEAT Jelly for "Edible Hydration" First new form of POCARI SWEAT since initial launch 36 years ago
Nutraceuticals
Thirst-quenching beverage aims to help women maintain optimum day-to-day condition Renewed Version of POCARI SWEAT Ion Water
Nutraceuticals
Otsuka Pharmaceutical Signs Health Promotion Support Agreement with Hyogo Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Partnership with Hiroshima Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters into Disaster Relief Supply Agreement with Ishikawa Prefecture
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership with Okayama Prefecture
Nutraceuticals
New casual soy bar with the pleasant crunchy texture of puffed soy "SOYJOY Crispy" Debuts in Three Flavors
Nutraceuticals
Otsuka Pharmaceutical Supports 37,000 Runners with Nutritional and Rehydration Products and Cadre of Blue Volunteers at Tokyo Marathon 2016
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors (PDF: 40.6 KB)
Pharmaceuticals
ABILIFY for Extended Release Injectable Suspension, Used to treat Schizophrenia, Has Received Approval in Japan for Administration at Deltoid Muscle Site
Pharmaceuticals
Anti-epileptic Drug E Keppra® (generic name: levetiracetam) Obtains Additional Indication of Adjunctive Therapy for Generalized Tonic-Clonic Seizures in Japan
Pharmaceuticals
Takeda Obtains NDA Approval for Helicobacter pylori* Eradication triple-drug Blister Packs Containing TAKECAB tablet, "VONOSAP® pack 400", "VONOSAP® pack 800" and "VONOPION® pack" in Japan
Pharmaceuticals
Otsuka Announces Worldwide Access Plan for Delamanid with Stop TB Partnership's Global Drug Facility
Nutraceuticals
Otsuka Pharmaceutical Enters Partnership Agreement with Aomori Prefecture on Health Literacy* Enhancement
Nutraceuticals
Otsuka Pharmaceutical to Support Japan Anti-Doping Agency's Official Sports Pharmacist Certification System
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Health Promotion Partnership with Tokushima Prefecture
Pharmaceuticals
Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis
Pharmaceuticals
Otsuka's Subsidiary Avanir Pharmaceuticals Announces U.S. FDA Approval of ONZETRA™Xsail™ for the Acute Treatment of Migraine in Adults
Nutraceuticals
Otsuka Pharmaceutical Forms Joint Venture Company for Functional Food and Beverages in the Philippines
Nutraceuticals
Otsuka Pharmaceutical Enters Into Comprehensive Health Promotion Partnership with Iwate Prefecture
Pharmaceuticals
Otsuka and ARIAD Announce New Drug Application for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia
Nutraceuticals
Otsuka Pharmaceutical Concludes Cooperative Agreement to Maintain and Promote Healthy Lifestyles with Shiga Prefecture
Pharmaceuticals
Winner Announced for the 2015 Young Innovator in TB Research Award
Pharmaceuticals
Otsuka Files for Approval in Japan for an Additional Indication for the Antipsychotic ABILIFY: Excitability Associated with Juvenile Autism
Nutraceuticals
Otsuka Pharmaceutical Concludes Comprehensive Agreement for Community Health Initiatives with Fukuoka Prefecture
Nutraceuticals
POCARI SWEAT Launched in Cambodia on December 1, 2015
Pharmaceuticals
E Keppra® Injectable, to be Launched in Japan on December 1; Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged 4 and Over with Partial-onset Seizures
Pharmaceuticals
Otsuka Pharmaceutical Affiliate Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients with Alzheimer's Disease
Nutraceuticals
Nature Made Ginkgo Biloba Otsuka Pharmaceutical Introduces Japan's First Food with Specific Function Claim for Cognitive Functions
Corporate
10,000 Attend 7th Asan Walking Festival in Itano on November 15 Cosponsored by Otsuka Pharmaceutical Tokushima Itano Factory
Nutraceuticals
Acquisition of BIOCENTURY, Leading Spanish Health and Functional Food Company
Nutraceuticals
Otsuka Pharmaceutical Named "Best Communicator" 'Heatstroke Prevention Communication Project' Hitosuzumi Awards 2015
Pharmaceuticals
New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
Pharmaceuticals
U.S. FDA Accepts First Digital Medicine New Drug Application for Otsuka and Proteus Digital Health
Nutraceuticals
Three New SOYJOY Bars, Enhanced with More Fruit, More Flavor Raisin, Apple and Hawthorn Berry
Nutraceuticals
Three Nature Made Products Receive Foods with Function Claims Labels specify benefits for eyes and inhibition of triglyceride levels in the blood
Nutraceuticals
Omugi Gohan Barley Rice from OMUGI SEIKATSU Receive Food with Function Claims Labels specify three benefits, including control of glucose absorption
Pharmaceuticals
Otsuka Pharmaceutical's Subsidiary Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 in the U.S.
Nutraceuticals
New Pen-type UL·OS Medicated Skin Whitening Helps Men Avoid Dark Spots and Freckles by Inhibiting Melanin Formation
Pharmaceuticals
Otsuka Pharmaceutical's Subsidiary Astex Enters New Consortium for Drug Discovery Research at the University of Cambridge
Pharmaceuticals
Efficacy Results of Otsuka's Delamanid (Deltyba™) for Extensively Drug-Resistant Tuberculosis (XDR-TB) Published in the New England Journal of Medicine
Pharmaceuticals
U.S. FDA Approves Otsuka and Lundbeck's REXULTI® (brexpiprazole) as Adjunctive Treatment for Adults with Major Depressive Disorder and as a Treatment for Adults with Schizophrenia
Nutraceuticals
Otsuka Pharmaceutical Continues the Overseas Distribution Expansion of POCARI SWEAT East Timor Market Official Launch July 1, 2015
Nutraceuticals
Otsuka Pharmaceutical Enters Into Health Promotion Partnership Agreement with Saitama Prefecture
Nutraceuticals
Renovation of POCARI SWEAT Factory at Tianjin Otsuka Beverage Co., Ltd. Visitor-friendly Factory Conveys the Importance of Ions and Fluid Replenishment
Pharmaceuticals
Otsuka's JINARC® the First-Ever Treatment Approved in Europe for Adults Living with ADPKD, a Chronic Genetic Kidney Disease
Nutraceuticals
Overseas Distribution of ORONAMIN C DRINK Expands to Hong Kong Otsuka Pharmaceutical to Launch Carbonated Nutritional Beverage in Rapidly Growing Hong Kong Market
Pharmaceuticals
New Treatment Option in Japan for People Living With Schizophrenia - Abilify for Extended-release Injectable Suspension, for Intramuscular Use, Launched on May 25
Nutraceuticals
Kenja-no-shokutaku Double Support Makes Overseas Debut in Hong Kong
Pharmaceuticals
Results of Phase III Study of Brexpiprazole in Adult Patients with Schizophrenia Published in American Journal of Psychiatry
Nutraceuticals
Review of research on use by menopausal women of nutritional supplement equol appears in US women's health publication
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Otsuka's Major BCR-ABL mRNA Measurement Kit Covered by Health Insurance in Japan as of April 1
Pharmaceuticals
Pre-Filled Dual Chamber Syringe for Abilify Maintena® (Aripiprazole) Prolonged-Release Suspension for Injection, Used in the Treatment of Schizophrenia, Received Positive CHMP Opinion (Approval in EU)
Pharmaceuticals
Otsuka Granted Approval in Japan for a New Formulation of ABIILIFY - ABILIFY for Extended-release Injectable Suspension, for Intramuscular Use - Indicated for Schizophrenia
Pharmaceuticals
Novel Anti-epileptic Drug E Keppra® Filed in Japan for Additional Indication of Adjunctive Therapy for Generalized Tonic-clonic Seizures
Pharmaceuticals
New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
Pharmaceuticals
The Union and Otsuka Open Nominations for 2nd Global TB Research & Innovation Award
Nutraceuticals
Celebrating 50 Years of ORONAMIN C DRINK
Nutraceuticals
New SOYJOY With More Fruit! Renewed Strawberry and Blueberry Versions Contain More Fruit
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints Board Members and Statutory Auditors (PDF: 41.2 KB)
Nutraceuticals
Otsuka Pharmaceutical, Otsuka Wellness Vending and Asahi Soft Drinks Form Business Partnership for Vending Machine Sales
Pharmaceuticals
Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area
Pharmaceuticals
CHMP Recommends JINARC® (Tolvaptan) for Approval in EU: The First Pharmaceutical Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
First-ever treatment approved in Canada for adults living with ADPKD, a life-threatening kidney disease
Corporate
Otsuka Pharmaceutical Receives Princess Chichibu Memorial Award for Distinguished Service to Tuberculosis Elimination
Pharmaceuticals
TAKECAB® Now Available for the Treatment of Acid-related Diseases in Japan
Pharmaceuticals
Novel Anti-epileptic Drug E Keppra® Approved in Japan for Additional Indication as Monotherapy for Partial-onset Seizures, in Addition to Existing Indication as Adjunctive Therapy for These Seizures
Nutraceuticals
New UL・OS Facial and Body Wipes
Nutraceuticals
Supporting Tokyo Marathon Runners with Beverages and Nutrition Before, During, and After the Race
Corporate
Notice of Change of Representative Director (Concurrent Obituary) (PDF: 128.1 KB)
Nutraceuticals
Otsuka Pharmaceutical Expands Overseas Distribution of ORONAMIN C DRINK Carbonated nutritional beverage to be produced and sold in South Korea
Corporate
Otsuka Australia Pharmaceutical Pty Ltd Opens in Australia
Pharmaceuticals
Terminations of Otsuka's Contract With OncoTherapy Science, Inc. on a Candidate Therapeutic Vaccine for Pancreatic Cancer and Otsuka's Sublicensing Contract With Fuso Pharmaceutical Industries for the Marketing of a Candidate Therapeutic Vaccine, OTS102
Pharmaceuticals
New Drug Application Approval of TAKECAB® for the Treatment of Acid-related Diseases in Japan
Pharmaceuticals
ARIAD and Otsuka Announced Co-development and Commercialization Agreement for Iclusig® to Treat Leukemias in Japan and Nine Other Asian Countries
Nutraceuticals
Otsuka Pharmaceutical Saga Nutraceuticals Research Institute Strengthens Focus on Sports Nutrition Completion of New Artificial Environment Control Room
Nutraceuticals
Otsuka Pharmaceutical Acquired US-based FoodState Inc. Growing Supplement Business Through New Channels
Pharmaceuticals
Otsuka And Lundbeck's Brexpiprazole Demonstrates Statistically Significant Effects In New Phase III Studies In Adult Patients With Schizophrenia Presented At The American College Of Neuropsychopharmacology Annual Meeting
Pharmaceuticals
Otsuka And Lundbeck Present Phase III Data on Brexpiprazole As Adjunctive Therapy In Adult Patients With Major Depression At The American College Of Neuropsychopharmacology Annual Meeting
Pharmaceuticals
U.S. FDA Approves The Labeling Update Of Abilify Maintena ® (Aripiprazole) For Extended-Release Injectable Suspension To Describe New Clinical Data For The Treatment Of Acutely Relapsed Adults With Schizophrenia
Corporate
Otsuka Pharmaceutical To Acquire Avanir Pharmaceuticals (PDF: 420.2 KB)
Pharmaceuticals
L-Cartin® FF Tablets For Carnitine Deficiencies To Be Introduced in Japan on December 5 Active Ingredient Carnitine in Free Form (FF*) to Address the Needs of Medical Field
Nutraceuticals
Nutrition & Santé Inaugurates New Factory Expanding Production Base of the French Leader in Functional and Dietetic Foods
Corporate
Otsuka Group Establishes New Company in Order to Strengthen Presence in Vending Machine Market
Corporate
Otsuka Pharmaceutical Tokushima Itano Factory Cosponsors 6th Asan Walking Festival in Itano Environmentally And Human-friendly Facility Maintains Close Ties to The Local Community
Nutraceuticals
New product for Japanese women Nature Made Fish Oil Pearl Small Pearl-shaped Capsules Concentrated With Essential Nutritional Balance of Fish Oil
Pharmaceuticals
Otsuka Pharmaceutical's QuickNavi™-Flu Influenza Diagnostic Kit to Provide Additional Diagnosis-Related Information
Nutraceuticals
Calorie Mate Recipient of "G Mark" Good Design Long Life Design Award
Pharmaceuticals
U.S. FDA Accepts Otsuka and Lundbeck's Filing for Review of Brexpiprazole for the Treatment of Schizophrenia and as Adjunctive Therapy for the Treatment of Major Depression
Nutraceuticals
Otsuka Pharmaceutical Launches "Next Generation Athlete Development Project" at the 17th Asian Games Junior athletes experience world-class atmosphere at Asia's largest competition
Pharmaceuticals
A Marker to Monitor Treatment Effectiveness For Chronic Myeloid Leukemia(CML) Approval in Japan for Otsuka's Major BCR-ABL mRNA Measurement Kit
Nutraceuticals
New Calorie Mate Block "Plain" First simple, unadorned flavor marks a return to Calorie Mate origins after 32 years
Nutraceuticals
New SoyCarat Chili Pepper Flavor Spicy version of healthy, low GI soy snack packs grown-up appeal
Pharmaceuticals
A Change in the Treatment of Multidrug-Resistant Tuberculosis Begins New Antituberculosis Drug Deltyba® in 50 mg Tablets, Available to Patients in Japan Starting September 26
Nutraceuticals
Acquisition of Jasmine, Leading Brazilian Health Food Company
Nutraceuticals
UL･OS Announces New Skin Conditioner Promoting the Habit of Skin Care for Middle-Aged Men
Corporate
Otsuka Welfare Clinic for Refugees in Pakistan Awarded Foreign Minister's Commendation
Pharmaceuticals
E Keppra® 500 mg Injectable For Monotherapy Treatment of Epilepsy Submitted For Regulatory Review in Japan
Pharmaceuticals
Otsuka and Lundbeck Submit New Drug Application in The US for Brexpiprazole for The Treatment of Schizophrenia and as Adjunctive Therapy for The Treatment of Major Depressive Disorder
Pharmaceuticals
After 40 Years, A New Drug For The Treatment Of Tuberculosis In Japan Deltyba® (delamanid) Is The First Drug Approved In Japan Specifically For Pulmonary Multidrug-Resistant Tuberculosis (MDR-TB)
Pharmaceuticals
E Keppra® Injectable Receives Marketing Authorization in Japan Will Contribute to Uninterrupted Treatment of Epilepsy Patients Aged Four and Over
Pharmaceuticals
Regulatory Approval Received in Japan For L-Cartin® FF Tablets 100 mg・250 mg Doses That Incorporate Carnitine in Free Form (FF*) Enables Medical Professionals to Conveniently Switch Patients Among the Three Free-Form Formulations – Tablet, Oral Solution and Injection
Pharmaceuticals
Meptin®, a Fast-acting Bronchodilator to Treat Asthma and COPD, Will Become Available in Japan on July 2 in a New Form as Meptin® Swinghaler® 10μg 100Puffs
Pharmaceuticals
Launch in Japan of Samsca 30 mg Tablet Formulation for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD), an Orphan Disease
Nutraceuticals
Otsuka Pharmaceutical Named the Major Official Sponsor of Inter-High School Athletic Championships for Two Consecutive Years Special Website Features Fan-produced Support Movies and First Streaming Broadcast of All Competitions
Nutraceuticals
Otsuka's POCARI SWEAT Aims the Very First Moon Landing Private Firms Take the Lead in the Start of "LUNAR DREAM CAPSULE PROJECT" Delivering all children's dreams 380,000KM to the moon
Pharmaceuticals
Otsuka Wins European Marketing Authorization for Deltyba™ (delamanid)
Nutraceuticals
New SOYJOY Almond & Chocolate Combines Crunchy Almonds, Subtly Sweet Chocolate and the Goodness of Soy The Perfect Snack for Busy Business People
Nutraceuticals
POCARI SWEAT ION WATER First Overseas Distribution Launched by King Car Otsuka in Taiwan
Pharmaceuticals
"QuickNavi Strep A" April 14 Market Launch in Japan Test Kit for the Rapid Detection of Group A Beta-hemolytic Streptococcal Antigen
Pharmaceuticals
Otsuka Acquires Rights to Hematological Cancer Treatment Dacogen® From Eisai (U.S.)
Pharmaceuticals
Otsuka and Takeda Announce a Co-promotion Agreement in Japan of TAK-438 For the Treatment of Acid-related Diseases in the Gastrointestinal Therapeutic Area
Pharmaceuticals
IBM and Otsuka Develop Transformative Care Coordination Solution
Nutraceuticals
On April 7, Otsuka Pharmaceutical Will Launch in Japan the Number-One Diet Food Product in France, "Milical"
Pharmaceuticals
Otsuka Pharmaceutical's Samsca® Approved in Japan as the World's First Drug Therapy for ADPKD, a Rare Kidney Disease
Nutraceuticals
Launch of EQUELLE Equol-containing food derived from soybeans A new option for women's health who are 40 and over during and after menopause
Pharmaceuticals
Anti-Epileptic Drug E Keppra® Filed in Japan for Additional Indication of Monotherapy for Partial-Onset Seizures
Corporate
Otsuka Pharmaceutical Opens a Second Day Care Center - the "Beanstalk Kids Center OSAKA" - at Otsuka's New Office Building in Osaka
Corporate
Otsuka Pharmaceutical was Awarded "Diversity Management Selection 100" from the Japan Ministry of Economy, Trade and Industry
Corporate
Agreement to Renew Memorandum of Understanding Between Otsuka Pharmaceutical and the Ministry of Health and Welfare of South Korea5-year extension of pharmaceutical research and development cooperation in South Korea
Pharmaceuticals
Otsuka's Antipsychotic Aripiprazole Awarded the 60th Okochi Memorial Prize
Nutraceuticals
Otsuka Pharmaceutical Supports the Tokyo Marathon 2014 Runners With Amino Value, the Official Beverage
Pharmaceuticals
Meptin Swinghaler, Easy-to-inhale Bronchodilator for COPD and Asthma Patients, Approved in Japan
Pharmaceuticals
Otsuka and Lundbeck Announce Once-Monthly Abilify Maintena™ Approved in Canada for the Maintenance Treatment of Schizophrenia in Stabilized Adult Patients
Pharmaceuticals
Otsuka and Lundbeck to present new data on brexpiprazole in major depressive disorder (MDD) at European Psychiatry Association 2014 Congress
Nutraceuticals
Otsuka Pharmaceutical's POCARI SWEAT to Be Official Drink for Two Consecutive Asian Games
Pharmaceuticals
Otsuka Pharmaceutical Submits Marketing Authorization Application in Japan for Abilify Once-Monthly Injectable Form for the Treatment of Schizophrenia
Pharmaceuticals
European Medicines Agency (EMA) Accepts Otsuka's Marketing Authorisation Application (MAA) for Tolvaptan, an Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Lundbeck and Otsuka to Co-Develop a Vaccine, Lu AF20513, Their Third Collaborative Development Project to Tackle Alzheimer's Disease
Corporate
Providing Free Health Care to Over 700,000 Afghan Refugees : The 10th Anniversary of the "Otsuka Welfare Clinic"
Pharmaceuticals
CHMP Recommends Otsuka's Deltyba™ (delamanid) for EU Approval for Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Combination with Optimized Background Regimen (OBR)
Nutraceuticals
New From the US, A Smart New Way to Take Vitamin and Mineral Supplements VitaMelts® Dissolve Smoothly Without Water Available at Convenience Stores Throughout Japan From November 25
Pharmaceuticals
Otsuka and Lundbeck's Once-Monthly Abilify Maintena® (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
Corporate
Otsuka Co-sponsors the Fifth Annual Asan Walking Festival in Itano on November 10
Pharmaceuticals
Otsuka Named as Lundbeck's Partner in Japan on Nalmefene for the Reduction of Alcohol Consumption
Nutraceuticals
Get the Dietary Fiber That is Missing From Your Diet*1With a Healthy Combination of Cereal Grains Otsuka Launches the New Products "Gerblé Multicereal Chocolate" and "Gerblé Multicereal Apricot"
Pharmaceuticals
Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-On Treatment for Alzheimer's Disease
Pharmaceuticals
Otsuka Pharmaceutical Receives the 2013 Good Design Award for the Antiplatelet Drug "Pletaal® OD Tablets"
Pharmaceuticals
Otsuka And Lundbeck Receive Postive Chmp Opinion In Europe For Abilify Maintena™, A Once-Monthly Injectable For Schizophrenia
Nutraceuticals
Two New Flavors of SoyCarat Nori & Natto and Olive Oil & Garlic Flavors Debut October 2
Pharmaceuticals
Vasopressin V2 Receptor Antagonist Samsca®7.5mg Tablets Granted Additional Indication in Japan for the Treatment of Fluid Retention in Patients with Hepatic Cirrhosis
Nutraceuticals
UL•OS Line of Men's Skin Care Marks 5th Anniversary Now Effective in Minimizing the Appearance of Fine Lines and Wrinkles Caused by Dryness
Corporate
Otsuka Pharmaceutical to Acquire Astex Pharmaceuticals
Pharmaceuticals
Otsuka Receives Complete Response Letter From U.S. Food And Drug Administration For Tolvaptan For Use In Patients With Autosomal Dominant Polycystic Kidney Disease
Pharmaceuticals
Japan's First Dry Syrup Formulation of an Anti-epileptic Drug for the Treatment of Partial-onset Seizures, E Keppra® Dry Syrup 50%, to Be Launched on August 29
Nutraceuticals
On September 1, Otsuka Launches "Omugi Seikatsu," a Healthy Breakfast Food With Barley Beta-Glucans
Pharmaceuticals
U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee Recommends Against Approval of Otsuka Pharmaceutical's Tolvaptan for Use in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Fingraph®, a fingertip blood sampler that conveniently measures sodium and potassium electrolyes in just one minute, debuts in Japan on August 6
Corporate
Come Check Out Our Brand New English Site! Global Website for Global Company Launches on Aug 1, 2013 http://www.otsuka.co.jp/en
Pharmaceuticals
Otsuka Receives Opinion from CHMP on Delamanid
Pharmaceuticals
Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer's disease*1 Lundbeck and Otsuka present data at Alzheimer’s Association International Conference 2013
Nutraceuticals
A Heat Wave Is Coming - Protect Yourself From Heat Stroke Otsuka's New "Heat Stroke Prevention Information" Service Launches July 8 Receive Automatic Updates on a "Heat Index" Indicating Your Heat Stroke Risk Level
Pharmaceuticals
Otsuka Europe Development and Commercialisation Ltd., a New Company for the Development of Pharmaceuticals Opens in the UK
Pharmaceuticals
Two New Formulations of E Keppra® Developed Dry Syrup Obtains Approval; Application Filed for Injectable Formulation Address various needs of patients with epilepsy from 4 years of age and contribute to improvement of compliance with medication
Pharmaceuticals
A New Choice of Therapy for the Treatment of Depression:ABILIFY® Granted Additional Approval as Adjunctive Therapy for the Treatment of Depression in Japan
Nutraceuticals
The No.1 pharmacist-recommended supplement*1「Nature Made」The First Supplement Facility was Built in Alabama*2.Production Capacity Increases 40% by 2014
Corporate
Otsuka has been selected by METI as a model enterprise for business continuity management
Pharmaceuticals
Otsuka Pharmaceutical Submits New Drug Application in Japan for Tolvaptan for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Pharmaceuticals
Vasopressin V2 Receptor Antagonist Samsca® 7.5mg Tablets To Be Launched in Japan on June 4 - Additional Choice of Dose for the Treatment of Volume Overload in Patients with Heart Failure
Pharmaceuticals
Antiepileptic Drug E Keppra® Tablet Approved in Japan for Pediatric Epilepsy (Partial-Onset Seizures)
Pharmaceuticals
Study Shows Effects of Treatment with ABILIFY MAINTENA™ (Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia
Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting
Pharmaceuticals
Otsuka Pharmaceutical's 44-member Employee Dance Group "Otsuka-Ren" Presented Traditional "Awa-Odori" of Tokushima, Where the Company Originates From, At Copenhagen Sakura Festival Held in Denmark
Pharmaceuticals
"Epi Diary" - An Epilepsy Diary Application for iOS A New Communication Tool for Patients with Epilepsy and their Physicians Now Available at https://itunes.apple.com/app/epi-diary/id616736809?Is=1&mt=8
Pharmaceuticals
Otsuka's New Drug Application For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD), Accepted For Review By The US Food And Drug Administration (FDA)
Nutraceuticals
New Version of POCARI SWEAT Low calorie beverage with subtle sweetness, refreshing after-taste POCARI SWEAT ION WATER Debuts April 8, 2013
Corporate
Like Having Everything At Your Fingertips? Then Check This Out! Otsuka Pharmaceutical Announces A Revamped Website April 1, 2013 http://www.otsuka.co.jp/
Pharmaceuticals
Otsuka's Novel Treatment for Multidrug-Resistant Tuberculosis, Delamanid, Submitted For Regulatory Approval in Japan -- Half Century Since Last Drug Was Approved in Japan for Tuberculosis
Pharmaceuticals
Lundbeck and Otsuka Further Expand Alliance and Enter Into Collaboration For the Development and Commercialization of Lu AE58054 In Development For Alzheimer's Disease
Pharmaceuticals
Otsuka Obtains Marketing Approval in Japan for Onglyza® Tablets to Treat Type 2 Diabetes; Transferred Rights to Kyowa Hakko Kirin
Nutraceuticals
"Weight Management with Chocolate" White Chocolate and Orange Chocolate Gerlinéa Meal Replacement Bars Debut on March 18
Nutraceuticals
The Healthy Benefits of Whole Soy Flavored with Crunchy Peanuts SOYJOY Peanuts Debuts April 24
Pharmaceuticals
Otsuka Advancing Rapidly in Central Nervous System Disorders; Expanding Its Existing Collaboration with Lundbeck
Pharmaceuticals
FDA Approves Once-Monthly ABILIFY MAINTENA™ (Aripiprazole) For Extended-Release Injectable Suspension for the Treatment of Schizophrenia
Pharmaceuticals
The First Transdermal Dopamin Agonist in Japan Neupro® Patch, For Both Parkinson's Disease and Restless Legs Syndrome, To Be Launched on February 26
Pharmaceuticals
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms for Carnitine Deficiency To Be Launched on February 26
Nutraceuticals
Otsuka Pharmaceutical Contributes to the Success and Development of the Tokyo Marathon as a Total Health Care Company Supporting Safe Running and Encouraging Runners to Complete the Full Distance with Amino Acids, Fluids and Electrolytes
Pharmaceuticals
7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist
Pharmaceuticals
The European Medicines Agency (EMA) Approves Aripiprazole (ABILIFY®) for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents.
Nutraceuticals
UL･OS Line of Men's Skincare Launches New SPF 50 & SPF 25 Sunscreens Applies Smoothly, Leaves No White Residue
Pharmaceuticals
Otsuka Pharmaceutical Files for Application of New Dry Powder Inhaler Product from the Meptin Brand
Nutraceuticals
French subsidiary Nutrition & Santé acquires gluten-free nutrition company from Lactalis Group
Pharmaceuticals
Otsuka and Lundbeck initiate the regulatory process for aripiprazole (once-monthly) depot formulation in Europe
Pharmaceuticals
L-Cartin® FF oral solution 10% and L-Cartin® FF injection 1000mg Two New Drug Forms approved for Carnitine Deficiency
Pharmaceuticals
The World's Only Transdermal Dopamin Agonist, Neupro® Patch, Approved in Japan for Both Parkinson's Disease and Restless Legs Syndrome
Nutraceuticals
Official Sponsor of Osaka Marathon for Second Consecutive Year Otsuka Pharmaceutical Will Continue to Support Safe Running and Encourage Runners to Complete the Full Distance
Pharmaceuticals
Otsuka Pharmaceutical and Abdi İbrahim Established a Joint Venture Company for Pharmaceutical Sales in Turkey
Corporate
Otsuka Pharmaceutical Tokushima Itano Factory to Cosponsor Asan Walking Festival in Itano A Portion of Entry Fees to be Donated to Great East Japan Earthquake Relief Efforts
Pharmaceuticals
Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial
Nutraceuticals
Kenja no Shokutaku Double Support Food for Specified Health Use with Dual Function Suppressing the Absorption of Both Sugars and Lipids, to Launch in Japan for the First Time
Nutraceuticals
Super Vitamin D, Containing the Daily Optimum Dose of Vitamin D in One Single Tablet Launched from Nature Made® - America's Number One Dietary Supplement Brand
Nutraceuticals
New "Poppy Seed & Lemon" from Gerblé to launch on October 15 The No.1 French Health Food Brand now in 3,000 stores nationwide
Pharmaceuticals
Kyowa Hakko Kirin Returns to Otsuka Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior to Hematopoietic Progenitor Cell Transplantation, in Japan and in Asian Countries & Regions
Pharmaceuticals
ABILIFY® ,The First Antipsychotic Agent in Japan Applying for Adjunctive Treatment in Major Depressive Disorder
Corporate
Otsuka, the First Pharmaceutical Company in Japan to Have Been Certified for "ISO22301", the International Standard for Business Continuity Management
Pharmaceuticals
Vasopressin V2-Receptor Antagonist, Samsca® Tablets Were Filed Additional Indication of the Treatment of Fluid Retention Associated with Cirrhosis of the Liver
Nutraceuticals
Pocari Sweat Launches in Vietnam through New Joint Venture Company. Vietnam Launch is the17th Market in the World Where the Pocari Sweat is Sold
Corporate
Otsuka Pharmaceutical × Nakacho, Tokushima Prefecture Largest Free Live Music Concert in Japan to Be Held
Pharmaceuticals
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome
Nutraceuticals
Otsuka Pharmaceutical To Boost Production Capacity and Increase Sales with Third Pocari Sweat Plant in Guandong Province,China
Pharmaceuticals
Proteus Digital Health, Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Worldwide Agreement to Develop Novel Digital Health Products
Pharmaceuticals
Otsuka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
Corporate
Reverse Daylight Savings Program to Shift Peak Energy Consumption
Pharmaceuticals
UCB Japan Files for Indication of Pediatric Epilepsy (Partial Onset Seizures) for E Keppra® Tablet; New Dry Syrup Formulation Filed at the Same Time
Nutraceuticals
Otsuka Pharmaceutical to Participate as Core Partner in TEDxTokyo 2012 to Connect Innovative Ideas to the Future
Pharmaceuticals
The New England Journal of Medicine Publishes Efficacy Results of Otsuka's Delamanid for Multidrug-Resistant Tuberculosis New Research Shows 53% Increase in Sputum Culture Conversion (SCC) After Two Months
Pharmaceuticals
The Federal Circuit Decision Affirming the Validity of the Asserted Claims of Otsuka's Patent to ABILIFY®
Pharmaceuticals
Results from a Phase 3 Study of Once-monthly Aripiprazole Intramuscular (IM) Depot Formulation for the Maintenance Treatment of Schizophrenia Presented at APA Annual Meeting
Pharmaceuticals
New Antipsychotic Agent "ABILIFY® OD Tablets" Pursues Agreeability for Patients, Enables easy Adherence
Nutraceuticals
Gérlinéa to Launch Nationwide −Enjoyable Calorie Control without Giving Up Sweetness−
Nutraceuticals
Breaking Conventional Rules of Snack Foods Healthy and Innovative Soy Snack "SoyCarat" Debuts
Corporate
Otsuka America Announces Personnel Changes (PDF: 182.2 KB)
Nutraceuticals
Otsuka Pharmaceutical Releases its UL・OS Brand of Men's Cosmetics in South Korea First overseas market for the brand after it was launched in Japan three and a half years ago
Nutraceuticals
Otsuka Pharmaceutical Supports the Tokyo Marathon for Six Years Running with Amino-Value Supporting the efforts of over 200,000 runners
Corporate
Heartful Kawauchi Co., Ltd., A Promoter of Employment for Persons with Disabilities, Receives Authorization as Special Subsidiary Company
Corporate
Otsuka Pharmaceutical's Fukuroi Factory Receives FY2011 METI Minister Award for Factories Making an Outstanding Contribution to the Environment
Pharmaceuticals
Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets"
Pharmaceuticals
Otsuka Pharmaceutical Files New Drug Application for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan
Pharmaceuticals
Otsuka Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders
Pharmaceuticals
Mucosta® ophthalmic suspension UD2% releases on January 5, 2012
Corporate
Otsuka Pharmaceutical Appoints New Director on Board (PDF: 64.1 KB)
Corporate
Otsuka Welfare Clinic awarded special commendation by the Ambassador of Japan in Pakistan Otsuka Welfare Clinic recognized for providing treatment over the past eight years to Afghan refugees in Pakistan
Nutraceuticals
Survey of bowel movements and fiber intake among children Approximately 40% of elementary school children do not have daily bowel movements Approximately 60% of mothers in this group feel their children lack fiber
Pharmaceuticals
New Drug Application for Otsuka's Once-monthly Aripiprazole Depot Formulation for Maitenance Treatment of Adult Patients With Schizophrenia Accepted for Review by the U.S. Food and Drug Administration
Pharmaceuticals
Streptococcus pneumoniae Kit “RAPIRUN S. pneumoniae HS (otitis media/sinusitis)” as in vitro diagnostic releases on December 1
Corporate
Tokushima Itano Factory jointly Sponsors Asan Walking Festival in Itano and Appeals for the Importance of Environmental Protection and Health
Corporate
OTSUKA PHARMACEUTICAL CO., LTD. AND H. LUNDBECK A/S Sign Historic Agreement to Deliver Innovative Medicines with Focus on Psychiatric Disorders Worldwide
Pharmaceuticals
Results of two trials show a rapid and sustained response with certolizumab pegol for treatment of rheumatoid arthritis (J-RAPID and HIKARI Studies) released at 2011 meeting of American College of Rheumatology (ACR)
Nutraceuticals
Amino-Value Used as the Official Drink of the Osaka Marathon 2011 Otsuka Pharmaceutical is Now Supporting Two of Japan's Largest Civic Marathons Amidst an Unprecedented Boom in Popularity in Japan
Pharmaceuticals
Otsuka Pharmaceutical Confirmed Clinical Efficacy of Rotigotine Transdermal System for Restless Legs Syndrome in Phase III Clinical Study in Japan
Nutraceuticals
～Easy Meal Replacement for Calorie Control ～ No. 1*French Slimming Dietetic Food Market Brand Gerlinéa Launches Cereal Bar in Chocolate and Vanilla Flavors
Nutraceuticals
Low-GI biscuit packed with fiber and bursting with five-grain cereal crunch Gerblé GLUCOSANTE Launches on October 3
Nutraceuticals
Healthy hair begins with a healthy scalp. Start your care routine from the scalp with UL･OS. UL・OS Scalp Shampoo（Medicated Cosmetic）Launches on September 13
Corporate
Notice Regarding Change of Director on Board (PDF: 73.4 KB)
Nutraceuticals
How intense is trail walking in the mountains for older people? This research suggests that muscle fatigue after trail walking may be reduced by BCAA supplementation.
Corporate
The Core of Globally Expanding Drug Discovery Research 10th Research Center wins the "Nikkei New Office Promotion Award" The Creativity-producing Office Space is Evaluated
Corporate
25,000 People Gather in Hilly Town of 10,000 for Free Live Concert Held at Tokushima Wajiki Factory Event Dedicated to Vitalization of Local Community
Corporate
Otsuka Pharmaceutical Establishes Special Subsidiary Company, Heartful Kawauchi Co., Ltd., in Tokushima City to Promote Employment of Persons with Disabilities
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' is Covered under Japanese Insurance Program, effective as of August.
Corporate
Partner Agreement Concluded between WASEDA University Athletic Center and Otsuka Pharmaceutical
Pharmaceuticals
The IFPMA Welcomes Otsuka Pharmaceutical as New Member to advance Global Health
Corporate
Otsuka Pharmaceutical Appoints Two Female Operating Officers for the First Time in the History of Its Pharmaceutical Business (PDF: 95.4 KB)
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF: 38.7 KB)
Pharmaceuticals
Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-
Pharmaceuticals
Otsuka receives approval for Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae HS (otitis media/sinusitis)" as in vitro diagnostic on June 13
Pharmaceuticals
Otsuka Announces Initiation of Phase I Clinical Trial for Therapeutic Cancer Vaccine OCV-105
Pharmaceuticals
Otsuka Pharmaceutical confirmed clinical efficacy of rotigotine trandermal system in Phase III clinical study in patients with advanced Parkinson's disease in Japan
Nutraceuticals
America's Number One-selling Vitamin, Mineral and Supplement Brand Five Years Running* - Nature Made New Series Providing Nutritional Support in a Single Tablet (or Softgel) Taken DailySuper Multiple Vitamin & Minerals and Super Fish Oil Set for June 6 Release
Nutraceuticals
Oronamin-C Drink First Small-Volume Vitamin Drink in Japan to Exceed 30 Billion Bottles in Accumulated Sales
Nutraceuticals
Gerlinéa, the No. 1 brand* for French Diet Food market ～Easy and Enjoyment; French Style Calorie Control～ Test Marketing Begins June 2, 2011 in Shizuoka and Tokyo
Corporate
Otsuka Pharmaceutical Establishes Subsidiary, Otsuka SA, to Facilitate Public Advocacy for the Company's Global Tuberculosis Program
Pharmaceuticals
Otsuka Pharmaceutical Co., LTD. Announces Results from a Phase 2 Study of Investigational Product OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder
Pharmaceuticals
Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011
Nutraceuticals
Handy Skin Care for Active Men UL•OS Refresh Sheet (Medicated Cosmetic) Launches on April 21
Pharmaceuticals
Otsuka Pharmaceutical Received Approval for Additional Indication of L-Cartin® tablets for Carnitine Deficiency in Japan
Corporate
Otsuka Pharmaceutical Announces Changes to Board Members (PDF: 58.5 KB)
Nutraceuticals
SOYJOY Fruity Tomato, a New Combination of Soy and Tomato, Launches on April 11
Corporate
Day Care Center for Children BeanStalk Kids Center TOKUSHIMA Opening April 1, 2011
Pharmaceuticals
ABILIFY® (aripiprazole) Approved for Maintenance Treatment of Bipolar I Disorder as an Adjunct to Either Lithium or Valproate Data from 52-week maintenance trial showed superiority of adjunctive ABILIFY versus adjunctive placebo on primary study endpoint
Corporate
Tokushima Itano Factory Awarded "Excellent Energy Management Factory" Commendation from Chief of Shikoku Bureau of Economy, Trade and Industry Achieves roughly 3.5% reduction in energy consumption efficiency unit
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes
Corporate
Otsuka Foods and Otsuka Pharmaceutical to Partner with ITO EN on Cross-Sales of Products in Vending Machines
Nutraceuticals
Sparkling Soy Water SOYSH Internet Buzz Leads to Its Distribution to Stores Nationwide in Japan Starting March 14, 2011
Pharmaceuticals
Otsuka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
Nutraceuticals
Nutraceutical Business in Europe Moves to New Stage SOYJOY, the First Japanese Product, Set to Debut in 4 Countries
Pharmaceuticals
Otsuka Pharmaceutical Files for Additional Indication Regulatory Approval in Japan for ABILIFY®, a Treatment for the Manic Symptoms Associated with Bipolar Disorder
Nutraceuticals
Amino-Value set to be the Official Drink of the Tokyo Marathon 2011 Support to Range from Training to Race Day
Pharmaceuticals
Starting co-promotion of the anti-cancer agent “SPRYCEL® Tablet 20mg and SPRYCEL® Tablet 50mg” (dasatinib) in Japan
Pharmaceuticals
The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL® (dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
Corporate
Defendants Appeal From Final Judgment in U.S. Abilify® Patent Litigation
Pharmaceuticals
World's First Aquaretic Agent for the Treatment of Volume Overload in Patients with Heart Failure Samsca® Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, to be Launched in Japan on December 14
Corporate
Tokushima Itano Factory Recognized Among "Corporate Greening Linked to Conservation of Biodiversity: Best 100" Sole factory manufacturing medical-use pharmaceuticals to receive recognition
Pharmaceuticals
Follow-Up Results from Study Comparing SPRYCEL® (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
Corporate
Toward a Factory that is Friendly to Both the Environment and People The Tokushima Itano Factory Helps to Support the Asan Earth Festival in Itano to be Held on November 23, 2010
Pharmaceuticals
Otsuka Pharmaceutical Files Application in Japan for Additional Indication of L-Cartin® Tablets for Carnitine Deficiency, Based on Evidences in Public Domain
Corporate
Otsuka Prevails in U.S. Abilify® Patent Litigation
Nutraceuticals
Clinical tests in Japan demonstrate research results relating to the efficacy of "Ion supply drink" for dehydration after bathing
Pharmaceuticals
Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye
Pharmaceuticals
FDA Approves SPRYCEL® (dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
SAMSCA™ Tablets 15mg (tolvaptan), Vasopressin V2-Receptor Antagonist, Receive Regulatory Approval in Japan
Nutraceuticals
New Release of Medicated Skin Wash in 500mL Pump-style Economy Size and Refill Pouch Available from November 12, 2010
Pharmaceuticals
OTSUKA ANNOUNCES PHASE 3 ARIPIPRAZOLE INTRAMUSCULAR (IM) DEPOT TRIAL INTERIM ANALYSIS REVEALS EFFICACY CRITERIA MET
Corporate
OTSUKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
Nutraceuticals
Tweet Runners app for iPhone released on September 29th Tweet Runners and Amino-Value keep runners going
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma
Pharmaceuticals
Antiepileptic Drug 'E Keppra® Tablet' with New Mechanism of Action Released on September 17
Pharmaceuticals
The Antiplatelet Agent Pletaal® (Nonproprietary Name: Cilostazol) The Results of CSPS 2, a Large-Scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Posted on the Online Version of The Lancet Neurology
Nutraceuticals
Renewed Package Design for Nature Made America's number one-selling vitamin, mineral and supplement brand
Corporate
Construction of 'OPS-5', New Plant to Manufacture Active Pharmaceutical Ingredients in Saga Factory Completed on September 1
Corporate
Publication of Environmental and Social Report 2010 - Featuring approaches to help build a low-carbon, recycling-oriented society, development of environment-conscious products and social action programs -
Corporate
21st Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki '10 on August 13, 2010
Pharmaceuticals
E Keppra® (levetiracetam) receives regulatory approval in Japan
Nutraceuticals
Care for delicate neck and decolletage areas InnerSignal Rejuvenate Clear-up Mask debuts September 1, 2010
Pharmaceuticals
SPRYCEL® (dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
Corporate
GW and Otsuka Agree Three Year Extension to Global Cannabinoid Research Collaboration
Pharmaceuticals
Otsuka receives approval for Rapirun® H. Pylori Antibody Stick as in vitro diagnostic device on June 8, 2010
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF: 38.5 KB)
Pharmaceuticals
Four-Year Follow-Up Data for SPRYCEL® (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
Pharmaceuticals
SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Pharmaceuticals
Otsuka Pharmaceutical to Introduce 1,300 iPad™ Units for Use as Multifunctional Pharmaceutical Information Tools
Nutraceuticals
A new style of “thoughtful gesture” Pocari Sweat Heartfelt Summer Letter Available at Post Offices throughout Japan from June 15
Pharmaceuticals
Streptococcus pneumoniae Kit "RAPIRUN S. pneumoniae" Approval obtained as in vitro diagnostic on May 26
Corporate
Indonesian affiliate PT. Amerta Indah Otsuka hosts May 26, 2010 dedication ceremony for Kejayan Factory - New Pocari Sweat production facility -
Nutraceuticals
Nature Made® Essential Nutrients for Modern Life Stlyes Introducing New Family Size Versions of Iron & Fish Oil（with EPA & DHA） Available from May 11, 2010
Corporate
Core of Global Basic Research Drug Discovery Research Building "10th Research Center" Completed on April 26
Pharmaceuticals
First Antithrombotic Orally Disintegrating Tablets Antiplatelet Agent "Pletaal® OD Tablets" Launched on April 26
Corporate
Otsuka Pharmaceutical to Exhibit Soylution Concept Video in Japan Industry Pavilion at Expo 2010 Shanghai
Nutraceuticals
A Refreshing New Concept: Whole Soy + Carbonate Sparkling Soy Water, SOYSH Debuts
Pharmaceuticals
Groundbreaking Ceremony for New Plant to Manufacture Active Pharmaceutical Ingredients held on April 8 at Saga Factory
Corporate
First reader-participation collaboration OTSUKA Health Comic Library Sequel Vol. 3 “We Are Children of the Earth: The Environment & Our Health” March 31 publication for donation to elementary schools nationwide
Pharmaceuticals
Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50
Pharmaceuticals
FerriSeltz® powder 20%, MRI Oral GI Contrast Agent, Receives Additional Approval for GI Negative Imaging in Cholangiopancreatography
Pharmaceuticals
Rapid Assay Kit for RS virus, QUICKNAVI™-RSV, Launch on April 6
Pharmaceuticals
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit "Otsuka" Application Filed for Additional Purpose of Use with Myelodysplastic Syndromes
Nutraceuticals
New Medicated Skin Wash from UL•OS Line of Men's Face & Body Care Available from April 22, 2010
Pharmaceuticals
The Results of CSPS II, a Large-scale Clinical Trial of Cilostazol in Preventing Recurrent Strokes, Presented at American Stroke Association's International Stroke Conference on February 26
Nutraceuticals
French Health Food Brand Gerblé to Debut in Japan Made from rigorously selected natural ingredients in southern France Test Marketing Begins April 6, 2010
Nutraceuticals
InnerSignal UV Protect Make-up Base b Will Be Launched on March 1, 2010
Corporate
Otsuka Pharmaceutical Co., Ltd. and Fuso Pharmaceutical Industries, Ltd. Conclude Agreement for the Manufacturing and Commercialization of Therapeutic Cancer Vaccine, OTS102
Corporate
Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration
Pharmaceuticals
U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
Nutraceuticals
New addition to CalorieMate® line of balanced nutrition blocks CalorieMate® Block, Maple Flavor First new flavor in two years debuts September 29
Nutraceuticals
New SOYJOY flavored with blueberries and white chocolate chips SOYJOY Blueberry Debuts September 29, 2009
Corporate
Otsuka Pharmaceutical Supports 8th Annual Wheelchair Basketball Camp in Ibaraki held from August 14-16, 2009
Corporate
20th Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki'09 on August 13, 2009
Pharmaceuticals
The European Commission Approves SAMSCA™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .
Nutraceuticals
Pocari Sweat in 900ml PET Eco-bottles New lightweight eco-bottles achieve 30% reduction in packaging weight
Corporate
Otsuka Pharmaceutical Co., Ltd -- Fiscal Year through March 2009 Non-consolidated Results of Otsuka Pharmaceutical Co., Ltd. (PDF: 298.2 KB)
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF: 157.8 KB)
Pharmaceuticals
FDA Approves SAMSCA™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia
Corporate
Otsuka Pharmaceutical Special Sponsorship Pocari Sweat U-12 Soccer League
Corporate
Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration
Corporate
20th Anniversary Edition Published March 31 OTSUKA Health Comic Library Sequel Vol. 2 "Explore! All About Our Bodies" Educational comic series donated to elementary schools nationwide
Nutraceuticals
Make-up removers formulated with moisturizing ingredient AMP expand the InnerSignal line of skin care products gentle, thorough removal of sebum and makeup
Pharmaceuticals
Antipsychotic agent ABILIFY® Oral Solution 0.1% to be Launched on April 10, 2009 in Japan
Corporate
Otsuka Pharmaceutical Supports Anti-Doping Efforts through Participation in “ Pharmacist” Project
Nutraceuticals
Third product in fruit soy bar SOYJOY 'Plus' series SOYJOY Banana Calcium Plus Debuts April 1, 2009
Nutraceuticals
Produced by Amino-Value“Virtual Tokyo Marathon 2009”Select your favorite avatar and challenge the 42.195km run
Corporate
Otsuka Pharmaceutical Established Otsuka Shanghai Research Institute in China for Innovative Drug Discovery Research
Nutraceuticals
UL・OS Line of Men's Skincare Launches Sunscreen Formulated with Moisturizing Ingredient AMP Initial launch in Kyushu and Okinawa, February 9
Corporate
Otsuka Pharmaceutical Co., Ltd. to acquire Nutrition & Santé, the European market leader in functional and dietetic foods
Nutraceuticals
Amino-Value Supports Tokyo Marathon 2009 as Official Drink BCAA Beverage to be Supplied as Support for 35,000 Runners
Corporate
Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration
Corporate
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration
Corporate
Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye
Nutraceuticals
Deliver moisture into skin UL•OS Men's Skin Care Line from Otsuka Pharmaceutical Debuts September 9, 2008
Nutraceuticals
New addition to fruit soy bar SOYJOY 'plus' series lineup SOYJOY Orange Folic Acid Plus Debuts October 1, 2008
Corporate
Otsuka Pharmaceutical Co., Ltd. Makes Capital Investment to Acquire Interpharma Praha, Czech Republic
Corporate
Exciting Summer in Wajiki '08 19th Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory August 13, 2008
Corporate
Notice of the Reorganization of Three Otsuka Group Companies (Otsuka Pharmaceutical Factory, Otsuka Warehouse, and Taiho Pharmaceutical) as Wholly Owned Direct Subsidiaries
Corporate
Otsuka Pharmaceutical Co., Ltd. Announces the Appointment of New President
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors
Corporate
Otsuka and UCB agreed to co-develop and co-promote Keppra® and Cimzia® in Japan
Corporate
Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A.
Corporate
Otsuka Pharmaceutical Co., Ltd. - Fiscal Year through March 2008 - Parent Company Results (PDF: 245.3 KB)
Corporate
Otsuka Pharmaceutical Co., Ltd. - Fiscal Year through March 2008 - Consolidated Results (PDF: 329.3 KB)
Pharmaceuticals
The first drug to be approved in Sweden for intermittent claudication: Pletal® is reimbursed
Corporate
OTSUKA Zoku Health Comic Library Vol. 1"Kids Who Eat, Play and Sleep, Grow"Educational comic series donated to elementary schools nationwide Published March 29
Nutraceuticals
Popular berry to be added to the SOYJOY lineup SOYJOY Strawberry Debuts April 1, 2008
Corporate
OTSUKA PHARMACEUTICAL ACQUIRES RIGHTS TO IV BUSULFEX FROM PDL BIOPHARMA
Corporate
Publication of Environmental and Social Report 2007
Pharmaceuticals
U.S. FOOD AND DRUG ADMINISTRATION APPROVES ABILIFY® (aripiprazole) AS THE FIRST MEDICATION FOR ADD-ON TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Nutraceuticals
New addition to fruit soy bar SOYJOY lineup SOYJOY Prune Fe Plus Debuts October 1, 2007 in Japan
Corporate
GW and Otsuka Enter into Global Cannabinoid Research Collaboration
Corporate
Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members
Corporate
New Symbol Signifying Otsuka Pharmaceutical's Corporate Philosophy Introduced on June 26, 2007
Corporate
Otsuka Pharmaceutical Co., Ltd.- Financial Results for the Year ended March 31, 2007 (PDF: 85.4 KB)
Nutraceuticals
SOYJOY Fruit Soy Bar launched in Taiwan by Otsuka Pharmaceutical affiliate, King Car Otsuka Co., Ltd.
Nutraceuticals
Fruit Soy Bar SOYJOY launched nationwide in US by Otsuka Pharmaceutical subsidiary, Pharmavite LLC
Corporate
GW and Otsuka Announce Major Long Term Strategic Cannabinoid Alliance
Corporate
Otsuka Pharmaceutical Co., Ltd. Announces Establishment of New Organization
Pharmaceuticals
Otsuka Pharmaceutical Europe and Schwarz Pharma Deutschland to Co-promote Antiplatelet Agent Pletal® in Germany
Pharmaceuticals
BRISTOL-MYERS SQUIBB AND OTSUKA PHARMACEUTICAL CO., LTD. ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR DIABETES COMPOUND SAXAGLIPTIN IN JAPAN
Pharmaceuticals
Antiplatelet Agent “Pletaal®” Co-Promotion Agreement between Otsuka Pharmaceutical and Chugai Pharmaceutical
Corporate
Publication of Environmental and Social Report 2006
Corporate
Strategic partnership agreement between Otsuka Pharmaceutical Co., Ltd. ('Otsuka Pharmaceutical') and Eiken Chemical Co., Ltd. ('Eiken Chemical') accompanied by the acquisition of a strategic stake in Eiken Chemical by Otsuka Pharmaceutical
Pharmaceuticals
Prix Galien awarded to Abilify® (aripiprazole) for medical innovation
Pharmaceuticals
Drug to treat schizophrenia with a new mechanism of action Antipsychotic agent "Abilify®" Available in Japan from June 8
Corporate
“The 15th Asian Games Doha 2006” POCARI SWEAT announced as the official sports drink for Doha 2006
Corporate
Considering the mechanisms of our bodies and health "OTSUKA New Health Comic Library" Release of Volume 5 "Future Drugs and Us" To be donated to junior high schools nationwide
Nutraceuticals
A new portable form of soybeans FRUIT SOY BAR “SOYJOY” To be released on April 3
Pharmaceuticals
Otsuka's Antipsychotic Abilify® Is Approved in Japan, January 23, 2006